Clinical Improvement Found After Administration of Acalabrutinib for Patients with COVID-19

A recent study, sparking further trials for investigation, saw improved clinical outcomes and reduced markers of inflammation for patients with severe COVID-19 after treatment with acalabrutinib, a selective BTK inhibitor.

Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news